Hedeker Wealth LLC Boosts Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Hedeker Wealth LLC grew its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 1.2% during the fourth quarter, HoldingsChannel reports. The firm owned 76,203 shares of the company’s stock after purchasing an additional 916 shares during the quarter. Hedeker Wealth LLC’s holdings in Harmony Biosciences were worth $2,622,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after acquiring an additional 436 shares during the last quarter. Mendota Financial Group LLC boosted its holdings in Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after acquiring an additional 965 shares during the last quarter. CWM LLC boosted its holdings in Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after acquiring an additional 775 shares during the last quarter. KBC Group NV raised its position in Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after purchasing an additional 819 shares during the period. Finally, Quantbot Technologies LP purchased a new position in Harmony Biosciences in the third quarter valued at about $74,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

NASDAQ HRMY opened at $38.78 on Friday. The stock has a market capitalization of $2.21 billion, a P/E ratio of 18.38, a P/E/G ratio of 0.51 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a 1 year low of $28.14 and a 1 year high of $41.61. The business’s fifty day moving average is $35.66 and its two-hundred day moving average is $35.42. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Insider Buying and Selling at Harmony Biosciences

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 19,293 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total transaction of $774,228.09. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jeffrey Dierks sold 1,629 shares of the business’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.02, for a total transaction of $61,934.58. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 72,452 shares of company stock valued at $2,831,679. Corporate insiders own 30.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on HRMY. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Harmony Biosciences in a research report on Monday, January 27th. Oppenheimer reiterated an “outperform” rating and issued a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Cantor Fitzgerald lifted their target price on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Needham & Company LLC reiterated a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a research report on Monday, January 13th. Finally, Mizuho boosted their target price on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.